CT-INTERACTIVE-BROKERS
Interactive Brokers Group , Inc. (NASDAQ GS:IBKR), a global electronic brokerage firm, began offering clients the ability to trade bitcoin futures at the start of trading on the Cboe Futures Exchange (CFE) on Sunday night, December 10th , 2017. In addition to offering bitcoin futures from the CFE, under the ticker symbol GXBT, the company plans to offer bitcoin futures from the Chicago Mercantile Exchange (CME) at the scheduled start of trading December 18th using the symbol BRR. IBKR was there at the start of trading and its systems operated normally.
“Interactive Brokers was on the buy side of the low print of 14,710,” said Thomas Peterffy, founder, Chairman and CEO of Interactive Brokers. “A Registered Investment Advisor on the Interactive Brokers platform purchased two March contracts in the first minute of trading.”
As of 9:15am ET on Monday, the company said that 201 of its accounts had placed 1,240 trades in bitcoin futures totaling 1,429 contracts representing approximately 50% of exchange recorded volume. The recorded value of all futures trades at Cboe exceeds $50 million.
The all-in commission rate, including exchange and regulatory fees, for bitcoin futures will be US $5.01 per contract for the Cboe product and US $15.01 per contract for the CME product. The CFE contract size is for one bitcoin, and the CME contract size is for five bitcoins. Old and new clients can learn more about trading bitcoin futures with IBKR and sign up for “Crypto” trading permission here .
Due to the extreme volatility of cryptocurrencies, clients will be unable to assume a short position. In addition, only limit orders will be accepted. IBKR’s margin requirement on long positions will be at least 50%. The company will continue to monitor concerns surrounding the market's ability to process bitcoin futures risk.
Clients can subscribe to live quotes for both Cboe and CME bitcoin futures.
About Interactive Brokers Group, Inc. Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities and foreign exchange around the clock on over 120 markets in numerous countries and currencies, from a single IB Universal AccountSM to customers worldwide. We service individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation has enabled us to equip our customers with a uniquely sophisticated platform to manage their investment portfolios at the lowest cost according to Barron's Best Online Brokers review, March 20, 2017. We strive to provide our customers with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low prices, positioning them to achieve superior returns on investments.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171211005806/en/
Contact:
Interactive Brokers Group, Inc.
Investors:
Nancy Stuebe,
203-618-4070
or
Media:
Kalen Holliday, 203-913-1369
Social Media:
https://www.facebook.com/InteractiveBrokers
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Receives Marketing Clearance for Lumipulse®G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease17.5.2025 08:58:00 CEST | Press release
—First Blood-Based In-Vitro Diagnostic Test to Receive FDA Clearancefor Patients Being Assessed for Alzheimer’s Disease. ——Availability of Accurate, Accessible, Blood-Based Diagnostic Tests Will Aid in Development and Availability of More Effective Interventions for Alzheimer’s Disease — Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with amyloid pathology associated with Alzheimer’s Disease (AD). Alzheimer’s disease currently affects an estimated 7.2 million Americans, a number projected to rise to nearly 14 million by 2060.1 It is a leading cause
IFF Announces Pricing of Tender Offers For Certain Outstanding Series of Notes16.5.2025 23:17:00 CEST | Press release
IFF (NYSE: IFF) announced today the Total Consideration (as defined below) payable in connection with its previously announced tender offers to purchase for cash: (i) up to $1,100,000,000 aggregate purchase price, excluding accrued and unpaid interest (the “Amended Pool 1 Maximum Amount”), of its 1.230% Senior Notes due 2025 (the “2025 Notes”), 1.832% Senior Notes due 2027 (the “2027 Notes”), 4.450% Senior Notes due 2028 (the “2028 Notes”) and 2.300% Senior Notes due 2030 (the “2030 Notes” and collectively with the 2025 Notes, the 2027 Notes and the 2028 Notes, the “Pool 1 Notes”) and (ii) up to $900,000,000 aggregate purchase price, excluding accrued and unpaid interest (the “Amended Pool 2 Maximum Amount” and, together with the Amended Pool 1 Maximum Amount, the “Amended Maximum Amounts”), of its 3.268% Senior Notes due 2040 (the “2040 Notes”), 4.375% Senior Notes due 2047 (the “2047 Notes”), 5.000% Senior Notes due 2048 (the “2048 Notes”) and 3.468% Senior Notes due 2050 (the “2050
Origins Launches in the U.S. Amazon Premium Beauty Store16.5.2025 15:00:00 CEST | Press release
The brand brings its high-performance, clinically proven, nature-inspired skincare to Amazon shoppers Origins, with over 30 years of expertise in combining naturally-derived and scientifically crafted ingredients for powerful skincare, announced its official debut in the U.S. Amazon Premium Beauty store today. Origins will offer its iconic skincare and body care products along with giftable sets that are perfect for any occasion. Origins will now bring naturally-derived, effective beauty to Amazon customers nationwide with convenience and thoughtful gifting in mind. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250516435958/en/ This launch marks a strategic step in Origins’ ongoing efforts to meet the evolving needs of skincare shoppers, seeking high-performance, conscious beauty on their favorite platforms. By expanding to the U.S. Amazon Premium Beauty store, Origins reinforces its commitment to delivering both efficacy a
The smarter E Europe 2025: Studies, Technologies and Market Trends for the Energy System of Tomorrow16.5.2025 12:47:00 CEST | Press release
Exactly one week has passed since The smarter E Europe closed its doors in Munich. Once again, Europe’s largest alliance of exhibitions for the energy industry turned the Bavarian capital into the epicenter of the global energy sector and impressed with outstanding results. Over the course of three days, 2,737 exhibitors from 57 countries showcased their technologies, business models and market-ready solutions for an intelligent, interconnected and fully renewable energy system. Around 107,000 professionals from 157 nations took the opportunity to connect, initiate partnerships and launch new projects. The accompanying conferences and side events also attracted strong interest, drawing more than 2,600 participants. The message sent out by The smarter E Europe and its four exhibitions – Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power Europe – was clear: We are the energy system. This press release features multimedia. View the full release here: https://www.businesswire.c
IFF Announces Early Tender Results and Increase of Tender Offers for Certain Outstanding Series of Notes16.5.2025 12:30:00 CEST | Press release
IFF (NYSE: IFF) announced today the early tender results for its tender offers to purchase for cash certain of its outstanding series of Notes. IFF also announced it has increased the previously announced Pool 1 Maximum Amount (as defined below) from $1,000,000,000 to $1,100,000,000 (the “Amended Pool 1 Maximum Amount”), the Pool 2 Maximum Amount (as defined below) from $800,000,000 to $900,000,000 (the “Amended Pool 2 Maximum Amount”, and together with the Amended Pool 1 Maximum Amount, the “Amended Maximum Amounts”), the 2027 Series Tender Cap (as defined below) from $300,000,000 to $400,000,000 and the 2050 Series Tender Cap (as defined below) from $600,000,000 to $649,114,000. The 2025 Notes Series Tender Cap and the 2040 Notes Series Tender Cap (each as defined below) remain unchanged at $500,000,000 and $450,000,000, respectively. Details of tender offers IFF initially offered to purchase for cash: (i) up to $1,000,000,000 aggregate purchase price, excluding accrued and unpaid in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom